--- Quote from: Tonny2 on July 19, 2024, 09:18:32 pm --- ojo. @JimAllen, my friend I forgot the ask you that send ne an invite, I can’t wait to see what the expert Michael have shared with you guys… please, Jim, I want to participate in the peer support group.
--- End quote ---
:) No problem. I'll add you to the future invites
Jim:
Micheal's full presentation
My notes:
* What HIV Does * What HIV Medications Do * Antiretrovial Medications * Antiretroviral Regimens * HIV replication (life) cycleEach stage can be a target for HIV drugs.
Cell Entry Attachment Inhibitors prevent the virus from attaching to the CD4 receptor capsid inhibitors interrupt the opening & unpacking of the capsid, preventing HIV infection of a cell.
Reverse Transcription (NNRTIs) attaches itself to reverse transcriptase and prevents the enzyme from converting RNA to DNA. (NRTIs) contain faulty nucleotides and when reverse transcriptase uses these faulty building blocks, the new DNA cannot be built correctly.
Integration (INSTI) Integrase inhibitors target a protein in HIV called integrase and block the integration
Transcription & Translation Assembly, Budding and Maturation
PIs block the activity of the protease enzyme & prevent the cell from producing new viruses. HIV capsid inhibitor, interferes with viral assembly.
Other drug classes Post-attachment inhibitors. CCR5 antagonists. Fusion inhibitors. Boosters Maturation inhibitors
Resistance
* Pre-treatment HIV drug resistance * Transmitted HIV drug resistance * Acquired HIV drug resistance Treatment
Currently, the standard treatment combines three or more antiretroviral medicines and more recently the increase of two drug therapy options.First-line treatment recommendations are an integrase inhibitor plus one or two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) (US mainly Bictavy). In low or middle-income countries WHO recommendations are for TLD (tenofovir disoproxil, lamivudine, dolutegravir)
Injectables, currently cabenuva. Although overall suppression rates in studies are similar to current treatments, concerns have been raised that when suppression failure occurs (virological failure), the acquired resistance % is very high with some publications showing 25-100%. *
*
* https://forums.poz.com/index.php?topic=77560.0 Doctors should be cautious when prescribing long-acting injectable cabotegravir and rilpivirine to patients with long and/or complex treatment histories. In addition, people with low CD4 cell counts or previous experience of AIDS were excluded from clinical trials, and might also be at risk of treatment failure. * https://forums.poz.com/index.php?topic=77637.0 Particularly older adults, women, POC are under-represented. Some evidence indicates treatment failure & developing resistance seems more common in HIV-1 subtypes A6 & A1 and also under those with a high BMI. More study is needed.
Tonny2:
ojo. Hello Jim!!…I bet lots of newbies didn’t even heard about all these class of medication and how different they attack the virus, this is the reason of the so called meds “ cocktail” that I guess we don’t use it anymore. Everything is just in one pill… I guess it is important to mention that, even though it’s been 40 years off medication research, we are still juicing some of all those old medication’s specially, I think they all this one that I can think of, lamivudina (3Tc), tenofovir TDF and ritonavir as booster for other antiretrovirus…good job Michael and Jim… keep up the good work… hugs
Tonny2:
--- Quote from: Jim Allen on July 20, 2024, 05:23:44 pm --- :) No problem. I'll add you to the future invites